Passage Bio, Inc. has reported promising interim results from its ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for frontotemporal dementia (FTD) with granulin (GRN) mutations. The treatment demonstrated significant improvements in two critical biomarkers of disease progression: a 64% reduction in whole brain atrophy and a 54% reduction in frontotemporal cortex atrophy at 12 months for patients with a global Clinical Dementia Rating (CDR) score of 1. Additionally, PBFT02 stabilized plasma neurofilament light chain (NfL) levels, contrasting sharply with the expected increase seen in untreated patients.

These findings suggest that PBFT02 may effectively slow neurodegeneration in early-stage FTD-GRN patients, as indicated by the robust and durable increases in progranulin levels observed in cerebrospinal fluid (CSF) samples. Specifically, patients receiving the higher dose of PBFT02 achieved an average CSF progranulin level of 22.8 ng/mL at 12 months, significantly above baseline levels. However, the FDA has mandated a randomized controlled trial for future registrational purposes, complicating the pathway forward due to ethical and logistical concerns associated with this rare disease.

The requirement for a randomized controlled trial could shift the landscape of clinical development for PBFT02, potentially extending timelines and increasing costs. This regulatory feedback necessitates a reevaluation of the clinical strategy, which may include exploring alternative development pathways or partnerships. As Passage Bio undertakes a strategic review to maximize shareholder value, the implications of these findings could influence not only PBFT02’s trajectory but also broader approaches to treating neurodegenerative diseases characterized by similar genetic underpinnings.

Source: globenewswire.com